24/7 Market News Snapshot 08 October, 2025 – GT Biopharma Inc. Common Stock (NASDAQ:GTBP)

October 8, 2025

DENVER, Colo., 08 October, 2025 (www.247marketnews.com) – (NASDAQ:GTBP) are discussed in this article.
GT Biopharma Inc. (NASDAQ:GTBP), recognized for its pioneering efforts in the immuno-oncology sector, is currently experiencing significant market interest. The company recently reported an impressive upswing in its stock price, opening at $0.789 and reaching $1.087, a striking increase of 44.61% from the previous closing of $0.752. With a current trading volume of around 16.95 million shares, investor engagement is evidently high as excitement builds around GT Biopharma’s potential breakthrough therapies.

The company is making notable advancements in its Phase 1 clinical trial of GTB-3650, designed to address relapsed or refractory CD33-expressing hematologic malignancies. GT Biopharma announced the successful enrollment and treatment of patients in Cohort 3, with early indicators of positive immune response and no reported dose-limiting toxicities. These developments reflect the preliminary findings from prior cohorts, which also demonstrated an encouraging level of immune activation.

The trial is strategically structured to progress through up to seven cohorts, enabling a thorough assessment of GTB-3650’s safety, pharmacokinetics, and potential therapeutic benefits. Cohort 3 has already begun to provide insights that may correlate enhanced immune responses with improved clinical outcomes. Moving forward, the company is preparing to initiate dosing for Cohort 4 by the end of 2025, fostering further investigation into the effects of GTB-3650.

GT Biopharma employs its proprietary TriKE® technology to amplify the natural immune defense mechanisms in patients, affirming its commitment to innovate cancer treatments. Collaboration with academic institutions like the University of Minnesota enhances the company’s research capabilities, positioning GT Biopharma as a vital contributor to oncology treatment advancements.

As the company continues its clinical development journey, the investment landscape remains optimistic about the transformative potential of GT Biopharma’s therapies for treating complex malignancies.

Related news for (GTBP)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.